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Abstract
Purpose—To assess the utility of US health insurance data for surveillance of hereditary 
hemorrhagic telangiectasia, an autosomal-dominant blood vasculature disorder with an estimated 
prevalence of 1.5–2.0 per 10,000 persons worldwide.
Methods—We used 2005–2010 MarketScan Research Databases to identify individuals with 
employer-sponsored health insurance and International Classification of Disease, 9th Revision, 
Clinical Modification codes of 448.0 present in either one inpatient claim or two outpatient claims 
30 days apart to define hereditary hemorrhagic telangiectasia. We examined frequencies of 
International Classification of Disease, 9th Revision, Clinical Modification codes for conditions 
that are complications of hereditary hemorrhagic telangiectasia among individuals with hereditary 
hemorrhagic telangiectasia and the general population to identify combinations of codes 
associated with hereditary hemorrhagic telangiectasia.
Results—Excluding observations from one state, the average prevalence of hereditary 
hemorrhagic telangiectasia was 0.3 per 10,000 persons. The reported prevalence rose with age 
from ~0.1 per 10,000 at ages <30 years to 1.0–1.1 per 10,000 at ages 70 years and above. The 
condition codes that were most specific to presumed hereditary hemorrhagic telangiectasia were 
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lung arteriovenous malformations and upper gastrointestinal angiodysplasia. Combinations of 
those codes and codes for brain arteriovenous malformation and epistaxis were highly predictive 
of reporting of hereditary hemorrhagic telangiectasia, with 20–57% of enrollees with those codes 
also meeting the study definition for hereditary hemorrhagic telangiectasia.
Conclusion—Hereditary hemorrhagic telangiectasia is underrecognized in US administrative 
data. Administrative health data can be used to identify individuals with combinations of signs that 
are suggestive of hereditary hemorrhagic telangiectasia. Studies are needed to test the hypothesis 
that referral for evaluation of individuals with administrative records suggestive of undiagnosed 
hereditary hemorrhagic telangiectasia could lead to diagnosis and access to life-saving treatments 
for both them and affected family members.
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INTRODUCTION
Rare disorders, defined in Europe as diseases affecting <1 per 2,000 people, are collectively 
an important public health issue but are typically underrecognized. A public health approach 
to rare disorders begins with assessments of the prevalence or incidence of these disorders 
and their impacts on health status, disability, mortality, and health services use.1
Surveillance for rare disorders is challenging. Population-based surveys typically lack 
sufficient numbers of observations, and many rare diseases are underreported. The primary 
source of information is usually patient registries, whether based on clinical referral centers 
or organized by disease advocacy organizations based on patient self-referral, but findings 
may not be generalizable to the entire population. Active population-based surveillance can 
be conducted through canvassing and review of medical charts,2 but that approach is time 
consuming and costly.
Passive surveillance conducted through the review of administrative health-care data can 
cover large populations at very low cost. Administrative health databases generally identify 
conditions through the use of International Classification of Disease diagnostic codes, either 
the International Classification of Disease, 9th Revision (ICD-9), used in the United States, 
or the 10th Revision (ICD-10), used in the rest of the world (and for mortality statistics in 
the United States). Two major types of administrative data are discharge records from 
hospitals and claims records from health insurers, whether private or public payers.3 The 
disadvantage is that those records lack validated diagnostic and clinical information.
The focus of this study is one specific rare disorder, hereditary hemorrhagic telangiectasia 
(HHT), which is also known as Osler–Weber–Rendu or Rendu–Osler–Weber syndrome 
(OMIM no. 187300). HHT is an autosomal-dominant disorder of blood vasculature, with an 
estimated prevalence of up to 2.0 per 10,000 persons worldwide.4,5 Mutations in two genes, 
endoglin (ENG) and activin A receptor type II–like 1 (ACVRL1), are associated with HHT1 
and HHT2, respectively. Three less common forms of HHT also exist, including one form 
associated with juvenile polyposis syndrome caused by mutations in the SMAD-related 
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protein 4 gene (SMAD4) and HHT3 and HHT4, for which loci have been determined but the 
genes have not yet been identified.6
HHT is a highly penetrant disorder, with the most common manifestation of recurrent 
epistaxis developing in 95% of individuals with HHT by the age of 50 years.7 HHT is 
characterized by the development of vascular malformations with direct artery-to-vein 
connection and loss of intervening capillaries. The smaller lesions, telangiectases, typically 
occur in the nasal, oral, or gastric mucosa or dermis of the hands or face, or in the liver. 
Chronic nasal or gastrointestinal (GI) bleeding is common and often results in the 
development of iron-deficiency anemia. The larger lesions, arteriovenous malformations 
(AVMs), typically occur in the lungs, brain, or liver and can cause life-threatening 
complications such as stroke, brain abscess, heart failure, and life-threatening hemorrhage.8 
Although different forms of HHT are associated with varying frequencies and timing of 
manifestation of signs or symptoms, the manifestations listed above occur in all types of 
HHT.9,10
The signs of HHT may go unrecognized and untreated for decades or cause premature 
death.11 A recent study from Italy involving 112 HHT patients who were index cases in their 
families reported that the mean age at which symptomatic disease manifested was 16.2 
years, the mean age of referral for evaluation of those symptoms was 31.7 years, and the 
mean age of diagnosis of HHT was 45.9 years, for a mean delay of almost 30 years between 
onset of symptoms and diagnosis.12 HHT is associated with significantly higher rates of 
premature mortality before 60 years of age.4,13
A definite diagnosis of HHT is established according to the international consensus Curacao 
Criteria by the presence of three of four criteria: epistaxis, multiple telangiectases, visceral 
lesions, and a family history with one or more first-degree relatives affected.14,15 Once an 
HHT diagnosis is established, screening and preventative management of AVMs is 
recommended14 and available in HHT Centers of Excellence (http://www.hht.org). As such, 
establishment of a diagnosis of HHT has important clinical implications, both for prevention 
and appropriate clinical care.
The purposes of surveillance for rare disorders such as HHT include a better understanding 
of the frequency of the disorder and its complications by age, race/ethnicity, and geographic 
location. Surveillance information can be used to guide the provision of health-care services 
and to evaluate the effectiveness and quality of medical care and interventions. In addition, 
understanding the characteristics of people who have undiagnosed HHT may help to guide 
the development of protocols for identifying such individuals using administrative data and 
referring them for evaluation for potential HHT. Improved identification can lead to 
screening for AVMs and the use of potentially life-saving treatments.14
The current study has three purposes. First, it assesses the prevalence of reported HHT 
among the US population with employer-sponsored insurance. Second, it assesses the 
frequency of reported symptoms characteristic of HHT both among people meeting the 
study definition for HHT and those with no HHT diagnosis code. Third, it seeks to identify 
the most specific combinations of signs and symptoms that are predictive of presumed HHT. 
Grosse et al. Page 3
Genet Med. Author manuscript; available in PMC 2015 June 03.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
The ultimate goal is to promote earlier diagnosis of HHT by using algorithms of 
combinations of diagnosis codes to identify patients who could be referred for HHT 
evaluation.
MATERIALS AND METHODS
The data for this study were derived from the 2005–2010 MarketScan Commercial Claims 
and Encounters and MarketScan Medicare Supplemental Research Databases (Truven 
Health Analytics, formerly the health-care business of Thomson Reuters). These databases 
arise from the processing of health insurance claims for reimbursement and include 
information on the diagnoses as submitted by providers. The MarketScan Commercial 
Database contains records on employer-sponsored insurance for employees and their 
dependents. It includes data from large and mid-sized, self-insured employers and employers 
who purchase fully insured health plans on behalf of their employees. The 2010 MarketScan 
Commercial Database had records on 45 million individuals younger than 65 years. The 
MarketScan Supplemental Medicare Database contains records on retired employees and 
spouses older than 65 years who are enrolled in Medicare with supplemental Medigap 
insurance paid by their former employers. All health-care services for which claims were 
submitted are covered. The 2010 Supplemental Medicare database includes 3.7 million 
individuals older than 65 years.
The MarketScan Research Databases are composed of separate databases for each year for 
enrollment, inpatient services, outpatient (including hospital emergency or ambulatory 
services, clinical visits, laboratory tests, and home healthcare) services, and outpatient 
prescription medications for those enrollees with prescription drug coverage. An encrypted 
individual identifier can be used to link records across databases and years to identify all 
records for unique individuals. The inpatient claim records allowed for up to 15 different 
ICD-9, Clinical Modification (ICD-9-CM) diagnosis codes, and the outpatient claim records 
allowed for two diagnosis codes to be listed between 2005 and 2008 and four diagnosis 
codes during 2009–2010. In addition to ICD-9-CM codes, the inpatient and outpatient 
databases listed procedure codes. The drugs database listed National Drug Classification 
codes but not ICD-9-CM codes. The only demographic variables for enrollees were age and 
sex. Provider type and location (three-digit zip codes) were included for both inpatient and 
outpatient databases.
To identify cases of HHT, all records from 2005 through 2010 for individuals with 
prescription drug coverage were analyzed. Cases of potential HHT were identified through 
use of the 448.0 ICD-9-CM diagnosis code, which in principle is specific to HHT. Any 
individual with a code of 448.0 in an inpatient record was classified as a case of HHT. In 
addition, individuals with two or more outpatient claims containing the 448.0 code for 
service dates more than 30 days apart were classified as cases of HHT. It is a standard 
practice in health services research using claims data to require more than one outpatient 
claim with a given diagnosis code separated in time in order to minimize “rule-out 
diagnoses” associated with outpatient services such as laboratory tests or radiology 
examinations when no diagnosis is found, in addition to minimizing coding errors.16,17 
Moreover, using multiple years of data for the same individuals improves the sensitivity of 
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ascertaining cases of chronic diseases, which may go unrecorded in services during a given 
year.17
Geographic variations in the reported frequency of HHT diagnoses were assessed according 
to census geographic region (Northeast, North Central, South, and West), state, and 
metropolitan area of residence, with three-digit zip codes aggregated to define state and 
metropolitan area of residence. Prevalence rates across regions and states were compared to 
determine potential clusters of HHT cases that might reflect different geographic patterns of 
coding or potentially the presence of large kindreds.
The frequency of other diagnoses associated with manifestations or signs of HHT on an a 
priori basis was compared between the presumed HHT cases and the remainder of the 
sample, excluding individuals with just one outpatient claim with an ICD-9-CM code of 
448.0 (n = 4,438), to identify those diagnoses that were most closely associated with 
presumed HHT. The other diagnoses comprised relatively specific signs of HHT as follows: 
epistaxis (784.7), telangiectasia (448.9), brain AVM (747.81), lung AVM (747.3, 417.0), 
unspecified AVM of the peripheral vasculature system (747.6), angiodysplasia of the upper 
GI tract (537.82, 537.83), and angiodysplasia of the intestine (569.84, 569.85). The 
following codes were considered by expert opinion to be potential but less specific markers 
of HHT: anemia: (280, 285), aneurysm or intracerebral hemorrhage (437.3; 431), acquired 
arteriovenous fistula (447.0), hemoptysis (786.3), and hemorrhage of the GI tract, 
unspecified (578.9). Although aneurysm is not a complication of HHT, the code may be 
miscoded to refer to a brain AVM.
Because recurrent epistaxis and the presence of multiple AVMs are expected to be more 
common among people with HHT, it was hypothesized that the presence of multiple claims 
for those signs would be higher among people meeting the study definition for presumed 
HHT. However, although multiple claims separated by time are likely to reflect multiple 
episodes, it is not possible using claims data to distinguish multiple from single AVMs 
diagnosed on one occasion.
RESULTS
During 2010, data on a total of 37,463,423 enrollees in the Commercial and Supplemental 
Medicare databases with prescription coverage were analyzed, of which 1,496 met the case 
definition for presumed HHT based on ICD-9-CM codes using records from 2005 through 
2010. An additional 4,438 individuals had just one outpatient claim with a code of 448.0 
during that period and were excluded from further analysis.
The overall prevalence of presumed HHT in the preliminary analysis was 0.40 per 10,000 
persons, which varied by region from 0.32 in the South to 0.40 in the West with a much 
higher prevalence of 0.56 in the North Central region (data not shown). The higher 
prevalence in the North Central region was concentrated in one state, Michigan, which had 
the highest apparent prevalence of presumed HHT, 2.00 per 10,000, accounting for 19.6% of 
presumed HHT cases and 3.9% of the MarketScan sample. Further analysis revealed that 
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few HHT cases in Michigan had diagnostic codes for manifestations or signs of HHT. To 
avoid potential bias, all records from Michigan were excluded from further analyses.
In the final data set, there were 1,203 HHT cases among 35,459,534 enrollees. The 
prevalence of presumed HHT in the North Central region (excluding Michigan) of 0.31 per 
10,000 was similar to the overall prevalence of 0.33 per 10,000 (Table 1).
As expected, the estimated prevalence of HHT increased with age (Table 1). It was ~0.1 per 
10,000 below 30 years, reached 0.53 at 50–59 years, and in the two oldest age groups, 70–79 
and 80 years and older, it was 1.14 and 1.04 per 10,000, respectively.
The frequencies and corresponding rate ratios of potential signs of HHT recorded among 
individuals with and without HHT are displayed in Table 2. The most common coexisting 
condition reported was anemia, which was reported for 50.0% of people with presumed 
HHT. Anemia is fairly common in the general population, reported for 5.6% of those 
without presumed HHT, and the resulting ratio is a relatively modest 9:1. Epistaxis was 
reported during 2008 for 34.2% of people with HHT but for only 0.8% of others, resulting in 
a ratio of 42:1. The most specific signs of HHT were lung AVM, with a ratio of 480:1, and 
upper GI angiodysplasia, with a ratio of 4,051:1, but these were reported for only 14.4 and 
8.1% of those with HHT, respectively. Other relatively specific diagnoses with ratios >100:1 
were unspecified AVM of the peripheral vasculature system (252:1), angiodysplasia of the 
intestine (178:1), and brain AVM (135:1).
The proportions of individuals with multiple claims for epistaxis, lung AVM, or brain AVM 
among those with any claim were only slightly higher among those with HHT (83.5, 78.8, 
and 70.5%, respectively) than those without an HHT diagnosis (61.0, 55.7, and 64.0%, 
respectively) (data not shown).
The frequencies of signs reported among those with HHT by broad age categories are 
depicted in Table 3. The most marked finding is that GI bleeding and anemia are uncommon 
before the age of 30 years among people with HHT but are increasingly common with 
advancing age. Conversely, a larger proportion of younger adults with HHT are recorded as 
having AVMs. Among adults older than 60 years with HHT, 18.7% had any type of AVM 
recorded on claims during 2010, as compared with 32.5% of those younger than 30 years.
Information on the frequency of pairwise combinations of signs is reported in Table 4, 
except that for angiodysplasia of the intestine only the interaction with lung AVM is 
reported. The six most specific combinations involve either lung AVM together with either 
upper GI angiodysplasia (rate ratio of 39,992), brain AVM (rate ratio of 17,997), 
angiodysplasia of the intestine (rate ratio of 15,426), other AVM (rate ratio of 12,665), or 
epistaxis (rate ratio of 7,791) or the combination of upper GI angiodysplasia with brain 
AVM (rate ratio of 7,831). Among people in the MarketScan 2010 databases who had one of 
these combinations of diagnoses, between 20 and 57% had HHT. These six combinations 
were reported for 111 (9.2%) of the 1,203 people with HHT, and for 454 (0.001%) persons 
without HHT diagnosis codes.
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The four other combinations of signs shown in Table 4 were more than 2,000 times more 
frequently observed in people with HHT than in the general population without an HHT 
diagnosis code, with positive predictive values of 7–12%.
DISCUSSION
The administrative prevalence of HHT, 0.3 per 10,000 US residents with employer-
sponsored health insurance, is substantially lower than estimates of 1.5–2 per 10,000 based 
on active, population-based surveillance studies conducted in Europe and Asia.4,5 This low 
frequency is consistent with previously reported US findings of a low degree of clinical 
recognition and reporting of HHT18 and hence is not surprising. A diagnosis of HHT 
requires that multiple criteria be met, including a family history of symptoms.14
At older ages, the frequency of HHT using the study case definition approaches the expected 
population frequency. Assuming that the presence of an ICD-9 code for 448.0 reflects a 
medical diagnosis of HHT, the majority of older adults with HHT are clinically recognized. 
However, late diagnosis of HHT is insufficient. Two older studies reported that HHT was 
associated with significantly elevated mortality below the age of 60 years;4,13 more recent 
data are lacking. Timely diagnosis enables appropriate clinical management of HHT and 
prevention of life-threatening complications. For example, preventative embolization of lung 
AVMs has been projected in a decision analysis based on clinical evidence to improve both 
life expectancy and health-related quality of life.19 Therefore, reducing underdiagnosis of 
HHT is a matter of public health importance.
The major potential contribution of the current study is the development of an approach to 
identify patients with combinations of signs or characteristics of HHT in order to refer them 
for evaluation of potential HHT. The study has identified six combinations of signs or 
symptoms that appear to be highly specific to the presence of billing codes for HHT, each of 
which occurs more than 2,000 times as frequently in people with presumed HHT (Table 4). 
Further study is warranted.
The reliance on administrative data and ICD-9 codes poses multiple limitations, and further 
investigation is warranted based on record linkage of administrative claims data for 
individuals and clinical records to validate the use of the 448.0 ICD-9-CM code for HHT. 
First, it is not known to what extent individuals with a medical diagnosis of HHT or with 
clinical suspicion of HHT have the 448.0 code listed. Second, it is possible that individuals 
meeting the study case definition may not actually have HHT.
Another limitation is that the signs or complications of HHT may not be reported in claims 
records. Conditions such as epistaxis or telangiectases may not be considered major and 
hence are not likely to be recorded for billing purposes. Serious complications such as 
AVMs are likely to be recorded while being actively managed. If an AVM is successfully 
embolized, it may not be recorded in subsequent years. Consequently, it is not surprising 
that the frequency with which classic signs of HHT are recorded in claims for people with 
HHT coded is substantially less than expected based on clinical data. In particular, lung or 
pulmonary AVMs, many of which are asymptomatic, are reported to occur in up to 50% of 
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people with HHT1 and 10–25% of people with HHT2.8 In the United States, HHT1 is 
slightly more common than HHT2.6,9 In the current study, 9% of people with HHT (13% 
among those aged 30–59 years) had a diagnosis of lung AVM recorded. In addition, the 
current study is representative of the US health-care system, and patients not seen at HHT 
centers may be less likely to have AVMs diagnosed and treated.
Another potential concern is that the 448.0 code does not necessarily indicate the presence 
of a medical diagnosis of HHT. In particular, not everyone aged 70 years or older meeting 
the case definition for HHT may have had HHT medical diagnoses. Fewer older adults with 
coded HHT had signs specific to HHT, e.g., epistaxis, telangiectasia, or AVMs, recorded in 
claims, and the majority had GI bleeding, anemia, or both as the main clinical signs. 
According to Canadian clinical data, anemia is found in 25% of HHT patients and 15% of 
non-HHT patients, a modest excess.20 By contrast, in the current study, anemia was 
recorded as a diagnosis among 49% of presumed HHT patients aged 30–59 years (Table 3) 
as compared with 5% of non-HHT patients (data not shown). Further investigation is 
warranted to investigate whether the 448.0 code may be used in some cases as a billing code 
in patients with unexplained GI bleeding and anemia. To validate the use of the 448.0 
ICD-9-CM code to ascertain cases of HHT, it is necessary to make a record linkage of 
administrative data for individuals with validated clinical HHT diagnoses.
This study has a number of other limitations. Some of those limitations are specific to the 
proprietary claims databases used, which comprise convenience samples of individuals with 
employer-sponsored insurance and are not representative of the US population. The only 
demographic variables available were age and sex. Race and ethnicity are not routinely 
collected by health plans in the United States unless directed by public payers and hence that 
information is not contained in the MarketScan Commercial or Medicare Supplemental 
databases.
On the other hand, claims data are superior to hospital discharge data for HHT surveillance. 
Although national hospital discharge data are representative of the entire population and 
include information on race/ethnicity, HHT is managed on an outpatient basis. According to 
the US Agency for Healthcare Research and Quality’s Health Care Utilization Project 
Nationwide Inpatient Sample of hospital inpatient discharges, during 1997 through 2010, 
there were an average of 3,500–4,000 discharges per year with a code of 448.0 listed 
(source: http://www.hcupnet.ahrq.gov/). This represents an annual HHT-associated 
hospitalization rate of a little more than 0.01 per 10,000 population.
More generally, the reliance on ICD codes in administrative data for case ascertainment has 
implications for the potential utility of such data for health services research on rare 
disorders. 1,3 Although administrative data are useful for research on disorders such as HHT 
or amyotrophic lateral sclerosis, for which there are highly specific ICD codes,21 the 
majority of rare disorders share codes with other, similar disorders. For example, although 
most people with Duchenne–Becker muscular dystrophy typically have health records 
listing one of two ICD codes, the majority of people who have those codes may have a 
different form of muscular dystrophy with different etiology, epidemiology, and 
symptoms.22
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A second limitation of administrative data is that medical information is not necessarily 
reported. For example, epistaxis is uncommonly recorded in billing records, probably 
because no medical treatment was prescribed. Of particular importance, it is not possible to 
reliably distinguish the presence of multiple AVMs from single AVMs in administrative 
data. Although HHT is not a common cause of brain AVMs overall, it is a leading cause of 
multiple brain AVMs. In a study of patients with brain AVMs, multiple AVMs were 
detected in 39% of those with HHT and only 1% of those without HHT.23 Consequently, 
individuals with multiple brain AVMs should be regarded as candidates for a work-up for 
HHT, the same as patients with both brain and lung AVMs.
Prospective studies are needed to validate these algorithms for case finding. An integrated 
health-care system’s database could be used to identify members with signs characteristic of 
HHT and to refer them for clinical evaluation. In addition, information contained in 
electronic medical records, such as the presence of multiple brain AVMs, could be used to 
improve positive predictive value. Although such an approach would not directly identify 
most individuals with undiagnosed HHT, it could identify index cases in many unrecognized 
HHT families. Once one member of a kindred is identified as having HHT and the causative 
genotype is found, it is straightforward and recommended to offer targeted molecular testing 
for the family-specific mutation to all first-degree relatives,14 50% of whom on average will 
also be affected by HHT. Such cascade testing of relatives can allow diagnosis in an entire 
family, followed by recommended screening and management.24,25
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Table 1
Prevalence of presumed HHT (ICD-9-CM code 448.0) in MarketScan Commercial and Supplemental 
Medicare Databases, 2005–2010, by age, sex, and region (excluding Michigan)
HHT (n) Population (n) Prevalence per 10,000
Age (years)
 0–9 55 4,663,310 0.12
 10–19 47 5,062,392 0.09
 20–29 58 4,646,957 0.12
 30–39 113 5,306,579 0.21
 40–49 203 5,914,142 0.34
 50–59 305 5,737,111 0.53
 60–69 237 2,983,016 0.79
 70–79 116 1,014,399 1.14
 ≥80 69 665,215 1.04
Sex
 Male 474 17,347,778 0.27
 Female 729 18,645,343 0.39
Region
 Northeast 173 5,256,430 0.33
 North Central 266 8,491,129 0.31
 South 468 14,648,998 0.32
 West 294 7,429,173 0.40
HHT, hereditary hemorrhagic telangiectasia; ICD-9-CM, International Classification of Disease, 9th Revision, Clinical Modification.
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